Cargando…
Hemophilia A: an ideal disease to correct in utero
Hemophilia A (HA) is the most frequent inheritable defect of the coagulation proteins. The current standard of care for patients with HA is prophylactic factor infusion, which is comprised of regular (2–3 times per week) intravenous infusions of recombinant or plasma-derived FVIII to maintain hemost...
Autores principales: | Porada, Christopher D., Rodman, Christopher, Ignacio, Glicerio, Atala, Anthony, Almeida-Porada, Graça |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263089/ https://www.ncbi.nlm.nih.gov/pubmed/25566073 http://dx.doi.org/10.3389/fphar.2014.00276 |
Ejemplares similares
-
In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
por: Almeida-Porada, Graça, et al.
Publicado: (2016) -
Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation
por: Mokhtari, Saloomeh, et al.
Publicado: (2016) -
Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021) -
Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery
por: Almeida-Porada, Graça, et al.
Publicado: (2020) -
Consensus statement from the first international conference for in utero stem cell transplantation and gene therapy
por: MacKenzie, Tippi C., et al.
Publicado: (2015)